Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.
Ophthalmic Plast Reconstr Surg
; 33(4): e82-e85, 2017.
Article
in En
| MEDLINE
| ID: mdl-27662198
ABSTRACT
Programmed cell death 1 (PD-1) inhibitors are members of a new class of drugs known as immune checkpoint inhibitors and have proven efficacy in the treatment of metastatic melanoma. Herein, the authors report the use of nivolumab and pembrolizumab, 2 recently Food and Drug Administration-approved PD-1 inhibitors, in 3 patients 1 with metastatic conjunctival melanoma and 2 with metastatic cutaneous melanoma and orbital involvement. The patients' metastatic disease responded well to drug treatment. As of this writing, 2 patients have completed therapy and remain disease free at least 1 year after treatment completion; the other patient is still receiving treatment, and his orbital disease is responding. The authors herein describe the use of PD-1 inhibitors as a new alternative in the treatment of metastatic melanoma to the orbit or metastatic ocular adnexal melanomas in these clinical settings.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Orbital Neoplasms
/
Conjunctival Neoplasms
/
Antibodies, Monoclonal, Humanized
/
Immunotherapy
/
Melanoma
/
Antibodies, Monoclonal
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
En
Journal:
Ophthalmic Plast Reconstr Surg
Journal subject:
OFTALMOLOGIA
Year:
2017
Type:
Article
Affiliation country:
United States